Augert et al. found that LSD1 inhibitor may achieve tumor regression and restore neuroendocrine (NE) phenotype in SCLC PDX by reactivating the NOTCH pathway (Augert et al., 2019). This evidence concerns the gene KDM1A and neoplasm.